<DOC>
	<DOC>NCT02531438</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.</brief_summary>
	<brief_title>Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Community-Acquired Infections</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients, ages 18 years or older who have signed the informed consent Has qualifying bacterial pneumonia Female patients must not be pregnant at the time of enrollment Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug Known or suspected hospitalacquired pneumonia Evidence of significant immunological disease Has a history of hypersensitivity or allergic reaction to any tetracycline or to any fluoroquinolone antibiotic Has received an investigational drug within past 30 days Women who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>